Ferroptosis-IN-23
Ferroptosis-IN-23 is an inhibitor of ferroptosis. Ferroptosis-IN-23 exerts a synergistic effect by simultaneously activating Steap4 and glutathione peroxidase 4 (GPX4), thereby maintaining iron metabolism homeostasis. Ferroptosis-IN-23 reverses neuronal ferroptosis and inhibits lipid ROS accumulation in cells. Ferroptosis-IN-23 inhibits ferroptosis in zebrafish, alleviates neuronal apoptosis, ROS accumulation, and dopaminergic neuron damage in a zebrafish model of Parkinson's disease. Ferroptosis-IN-23 can be used for research on Parkinson's disease.
For research use only. We do not sell to patients.
- Formula: C19H18N2O6
- Molecular Weight:370.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Ferroptosis-IN-23 (Compound 8h) (10 μM; 48 h) potently reverses ferroptosis in HT-22 hippocampal neurons induced by RSL3 (HY-100218A), Erastin (HY-15763), and Ammonium iron (III) citrate (FAC) (HY-B1645)[1].
Ferroptosis-IN-23 (5-20 μM; 48 h) inhibits RSL3-induced lipid ROS accumulation in HT-22 hippocampal neuron cells in a dose-dependent manner[1].
Ferroptosis-IN-23 (10-20 μM; 48 h) reverses RSL3-induced ferroptosis in Steap4-silenced HT-22 hippocampal neurons, with the 10 μM concentration restoring cell viability to 60.4%, indicating that Steap4 contributes to, but is not essential for, its anti-ferroptotic activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RSL3-treated HT-22 hippocampal neuronal cells
-
Concentration:10 μM (after 4 h pre-treatment with 0.1 μM RSL3)
-
Incubation Time:48 h
-
Result:Reversed RSL3-induced ferroptosis, restoring HT-22 cell viability to 74.3% relative to the control group.
-
Cell Line:erastin-treated HT-22 hippocampal neuronal cells
-
Concentration:10 μM (after 4 h pre-treatment with 0.3 μM erastin)
-
Incubation Time:48 h
-
Result:Significantly reversed erastin-induced ferroptosis in HT-22 cells, with superior activity relative to a comparator compound.
-
Cell Line:FAC-treated HT-22 hippocampal neuronal cells
-
Concentration:10 μM (after 4 h pre-treatment with 6 mM FAC)
-
Incubation Time:48 h
-
Result:Reversed FAC-induced ferroptosis in HT-22 cells.
-
Cell Line:Steap4-silenced, RSL3-treated HT-22 hippocampal neuronal cells
-
Concentration:10-20 μM (after 4 h pre-treatment with 0.1 μM RSL3 in Steap4-silenced cells)
-
Incubation Time:48 h
-
Result:Restored cell viability to 60.4% relative to the control group at 10 μM, while 20 μM showed further improved viability.
In Vivo
Ferroptosis-IN-23 (2-8 μM; 72 h) dose-dependently alleviates 6-OHDA (HY-B1081A)-induced neuronal apoptosis and ROS accumulation in wild-type AB strain zebrafish (a Parkinson's disease model)[1].
Ferroptosis-IN-23 (2-8 μM; 96 h) dose-dependently protects Tg (vmat2: GFP) zebrafish, a Parkinson's disease model, against MPTP (HY-15608)-induced dopaminergic neuron damage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type AB strain (2 hours post-fertilization)[1]
-
Dosage:2 μM; 4 μM; 8 μM
-
Administration:72 h
-
Result:Significantly reduced the number of apoptotic brain cells induced by RSL3.
Dose-dependently reduced RSL3-induced reactive oxygen species (ROS) accumulation in zebrafish brains.
Dose-dependently decreased RSL3-induced increases in lipid peroxidation (LPO) and malondialdehyde (MDA) levels.
Dose-dependently reduced RSL3-induced upregulation of hepcidin (HEPC) expression and restored ferroportin (FPN) expression.
Dose-dependently reversed RSL3-induced downregulation of glutathione peroxidase 4 (GPX4a and GPX4b) expression.
Dose-dependently restored RSL3-induced downregulation of Steap4 expression.
-
Animal Model:wild-type AB strain (2 hours post-fertilization)[1]
-
Dosage:2 μM; 4 μM; 8 μM
-
Administration:immersion; daily replenishment; 72 hours, followed by 24 hours of co-exposure with 6-OHDA
-
Result:Significantly reduced the number of apoptotic brain cells induced by 6-OHDA.
Dose-dependently reduced 6-OHDA-induced ROS accumulation in zebrafish brains.
-
Animal Model:Tg(vmat2: GFP) strain (1 day post-fertilization)[1]
-
Dosage:2 μM; 4 μM; 8 μM
-
Administration:immersion; daily replenishment; 96 hours with concurrent MPTP exposure
-
Result:Dose-dependently reversed MPTP-induced shortening of dopaminergic neuron regions, with recovery toward control levels.
Chemical Information
-
Molecular Weight 370.36
-
Formula C19H18N2O6
-
SMILES
O=C1NC(C(C2=CC=CC(OC)=C2)=O)=NC3=C1C(OC)=C(OC)C(OC)=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (270.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7001 mL | 13.5004 mL | 27.0008 mL | 67.5019 mL |
| 5 mM | 0.5400 mL | 2.7001 mL | 5.4002 mL | 13.5004 mL | |
| 10 mM | 0.2700 mL | 1.3500 mL | 2.7001 mL | 6.7502 mL | |
| 15 mM | 0.1800 mL | 0.9000 mL | 1.8001 mL | 4.5001 mL | |
| 20 mM | 0.1350 mL | 0.6750 mL | 1.3500 mL | 3.3751 mL | |
| 25 mM | 0.1080 mL | 0.5400 mL | 1.0800 mL | 2.7001 mL | |
| 30 mM | 0.0900 mL | 0.4500 mL | 0.9000 mL | 2.2501 mL | |
| 40 mM | 0.0675 mL | 0.3375 mL | 0.6750 mL | 1.6875 mL | |
| 50 mM | 0.0540 mL | 0.2700 mL | 0.5400 mL | 1.3500 mL | |
| 60 mM | 0.0450 mL | 0.2250 mL | 0.4500 mL | 1.1250 mL | |
| 80 mM | 0.0338 mL | 0.1688 mL | 0.3375 mL | 0.8438 mL | |
| 100 mM | 0.0270 mL | 0.1350 mL | 0.2700 mL | 0.6750 mL |
Ferroptosis-IN-23 Related Classifications
HY-181665 Related Classifications
Powered by Bioz